News
-
Cervical cancer prevention week 2020
20 January 2020
Cervical screening offers the greatest protection against cervical cancer with smear tests preventing 75% of cervical cancers but the number of women attending cervical screening in the UK is falling.
Read more -
Specialist cancer trust retains its ‘Outstanding’ rating
16 January 2020
The Royal Marsden NHS Foundation Trust has retained its ‘Outstanding’ rating as a Trust and ‘Outstanding’ rating for being well led following an inspection by the Care Quality Commission in September and November 2019.
Read more -
Chief Executive of The Royal Marsden awarded DBE in New Year Honours
27 December 2019
Cally Palmer, Chief Executive of The Royal Marsden NHS Foundation Trust, and National Cancer Director for NHS England and NHS Improvement, has been awarded a DBE for services to cancer medicine.
Read more -
World first treatment with ‘acoustic cluster therapy’ to improve chemotherapy delivery
18 December 2019
A patient at The Royal Marsden is the first in the world to receive chemotherapy assisted by an innovative new technology that uses microscopic clusters of bubbles and liquid droplets to enhance the delivery of drugs to tumours.
Read more -
Using ‘Vacuum’ technology to map out breast cancer
13 December 2019
The use of ‘vacuum’ power to take tissue samples from the breast, could help surgeons more accurately map out where cancer remains after chemotherapy according to new research led by The Royal Marsden NHS Foundation Trust.
Read more -
The Big Picture
12 December 2019
Using a liquid biopsy can identify rare mutations in advanced breast cancer, which may enable patients to access effective treatment quicker in the future.
Read more -
Advances in treatment for advanced breast cancer
11 December 2019
Researchers from The Royal Marsden NHS Foundation Trust have been involved in a seminal trial investigating new pioneering treatment for advanced breast cancer.
Read more -
Some men with advanced prostate cancer could live for two years or more on immunotherapy
27 November 2019
Some men with advanced prostate cancer who have exhausted all other treatment options could live for two years or more on immunotherapy, a major clinical trial has shown.
Read more -
The Royal Marsden scores highly in NHS Children and young people’s patient experience survey
26 November 2019
The Royal Marsden has scored amongst the top Trusts in the country for patient experience for children and young people, according to results published by the Care Quality Commission.
Read more -
Major trial backs immunotherapy as standard first-line treatment for head and neck cancer
24 November 2019
Immunotherapy is better than standard ‘extreme’ chemotherapy as first-line treatment for advanced head and neck cancer and can keep some patients alive for more than three years, a major new trial reports.
Read more